The Incidence of Cancer among Blood Donors

Merk, K.; Mattsson, Britta; Mattsson, Anders; Holm, G.; Gullbring, B; Björkholm, Magnus

doi:10.1093/ije/19.3.505

Cited by 81 publications

(62 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A third limitation is that the conclusions from this study may not be applicable to nonAsians because the cohort came from Taiwan. However, similar results were found from several studies on Caucasians (6, 7), whereas reductions of cancer risks by phlebotomy in blood donors were reported from non-Asian countries in America and Europe (9,38). In addition, the patterns of serum iron levels were grossly similar between this cohort and that of NHANES (23).…”

Section: Discussionsupporting

confidence: 89%

High Serum Iron Is Associated with Increased Cancer Risk

et al. 2014

View full text Add to dashboard Cite

Epidemiologic studies linking high serum iron with cancer risks are limited and inconclusive, despite evidence implicating body iron in human carcinogenesis. A cohort of 309,443 adults in Taiwan who had no history of cancer had serum iron levels tested at the time of recruitment (1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008). Initially measured iron levels were associated with subsequent cancer risk by linking individuals with the National Cancer Registry and National Death File. HRs were calculated by the Cox model. One third of males (35%) and one fifth of females (18%) had high serum iron (!120 mg/dL), which was associated with a 25% increase in risk for incidence of all cancers [HR, 1.25; 95% confidence interval (CI), 1.16-1.35] and with a 39% increase in risk for mortality from all cancers (HR, 1.39; 95% CI, 1.23-1.57). The relationship between serum iron and cancer risk was a J-shaped one, with higher cancer risk at both ends, either at lower than 60 mg/dL or higher than 120 mg/dL. At the higher end, cancer risk increased by 4% for every 10 mg/dL increment above 80 mg/dL, showing a dose-response relationship, with 60 to 79 mg/dL as a reference level. In a sensitivity analysis, the increases in risk were still observed after the first 5 years of cancer cases were excluded. Liver cancer risk was increased in HBV (À) non-hepatitis B carrier (3-fold) and HBV (þ) hepatitis B carrier (24-fold). Lifestyle risks such as smoking, drinking, or inactivity interacted synergistically with high serum iron and significantly increased the cancer risks. The liver (HR, 2.49; 95% CI, 1.97-3.16) and the breast (HR, 1.31; 95% CI, 1.01-1.70) were the two major cancer sites where significant cancer risks were observed for serum iron either !120 mg/dL or !140 mg/dL, respectively. This study reveals that high serum iron is both a common disorder and a marker of increased risk for several cancers. Cancer Res; 74(22); 6589-97. Ó2014 AACR.

show abstract

Section: Discussionsupporting

confidence: 89%

High Serum Iron Is Associated with Increased Cancer Risk

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In two previous studies (28,38), decreased cancer incidence was observed among blood donors; however, PV was a remarkable exception from this observation in one study.…”

Section: Discussionmentioning

confidence: 70%

“…The specific etiology of CMPD is unknown and obvious risk factors (irradiation, viral infections) have not been identified (26). Regular, artificial blood loss due to multiple blood donations was also reported in a surprising excess in the previous medical history of PV patients (27,28). It is conceivable that regular blood loss causing chronic iron deficiency or mild anemia may enhance the formation of CMPD as a consequence of long-term stimulated state of erythropoiesis.…”

Section: Introductionmentioning

confidence: 99%

HFEC282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease

Andrikovics

Meggyesi

Szilvási

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Iron metabolism has been implicated in carcinogenesis and several studies assessed the potential role of genetic variants of proteins involved in iron metabolism (HFE C282Y, TFR S142G) in different malignancies. Few reports addressed this issue with relation to chronic myeloproliferative disorders (CMPD). The aims of our study were (a) to examine the potential associations of CMPD development with genetic modifiers of iron metabolism in a large cohort of CMPD patients; (b) to examine associations of genetic variants of proteins involved in iron metabolism; and acquired JAK2 V617F mutation with clinical characteristics of CMPD. HFE C282Y was genotyped in 328 CMPD patients and 996 blood donors as controls, HFE H63D, and TFR S142G were tested in CMPD patients and 171 first time blood donors. JAK2 V617F mutation was tested in CMPD patients and in 122 repeated blood donors. Decreased C282Y allele frequency (allele frequency F 95% confidence interval) was found in the CMPD group (1.8% F 1.0%) compared with controls (3.4% F 0.8%; P = 0.048). TFR S142G allele frequency was reduced among V617F-negative CMPD patients (34.8% F7.6%) compared with controls (47.8% F 5.4%; P = 0.02). The frequency of JAK2 V617F was 75.9% (249 of 328) in the CMPD group. At presentation, elevated hemoglobin levels were found in V617F-positive patients compared with V617F-negative counterparts (P < 0.000). Vascular complications (26.6% versus 15.2%; P = 0.039) as well as female gender (57.4% versus 41.8%; P = 0.019) were more common in V617F-positive patients. We found that HFE C282Y might be associated with a protective role against CMPD. Because chronic iron deficiency or latent anemia may trigger disease susceptibility for CMPD, HFE C282Y positivity may be a genetic factor influencing this effect. (Cancer Epidemiol Biomarkers Prev 2009;18(3):929 -34)

show abstract

“…Therefore, even the modest increases in body iron stores seen in C282Y heterozygotes are associated with elevated cancer risk. A reduction in iron stores also appears to be protective: a significant reduction in overall cancer incidence (relative risk ratio 0.79) was observed in a large study of Swedish blood donors that was designed to test this hypothesis (42). The prescription of iron supplements and iron-containing multivitamins for real or perceived iron deficiency and the fortification of foods with iron are routine in the United States.…”

Section: Discussionmentioning

confidence: 99%

Increased Prevalence of theHFE C282YHemochromatosis Allele in Women with Breast Cancer

Kallianpur

Hall

Yadav

et al. 2004

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Individuals with the major hemochromatosis (HFE) allele C282Y and iron overload develop hepatocellular and some extrahepatic malignancies at increased rates. No association has been previously reported between the C282Y allele and breast cancer. We hypothesized that due to the pro-oxidant properties of iron, altered iron metabolism in C282Y carriers may promote breast carcinogenesis. Because 1 in 10 Caucasians of Northern European ancestry carries this allele, any impact it may have on breast cancer burden is potentially great. We determined C282Y genotypes in 168 patients who underwent high-dose chemotherapy and blood cell transplantation for cancer: 41 with breast cancer and 127 with predominantly hematological cancers (transplant cohort). Demographic, clinical, and tumor characteristics were reviewed in breast cancer patients. The frequency of C282Y genotypes in breast cancers was compared with the frequency in nonbreast cancers, an outpatient sample from Tennessee (n ‫؍‬ 169), and a published United States national sample. The frequency of at least one C282Y allele in breast cancers was higher (36.6%, 5 homozygotes/10 heterozygotes) than frequencies in Tennessee (12.7%, P < 0.001), the general population (12.4%, P < 0.001), and similarly selected nonbreast cancers (17.0%, P ‫؍‬ 0.008). The likelihood of breast cancer in the transplant cohort increased with C282Y allele dose (P trend ‫؍‬ 0.010). These results were supported by the finding in a nontransplant cohort of a higher frequency of C282Y mutations in Caucasian (18.4%, P ‫؍‬ 0.039) and African-American (8.5%, P ‫؍‬ 0.005) women with breast cancer than race-specific national frequency estimates. A high prevalence of C282Y alleles in women with breast cancer with and without poor risk features suggests that altered iron metabolism in C282Y carriers may promote the development of breast cancer and/or more aggressive forms of the disease.

show abstract

The Incidence of Cancer among Blood Donors

Cited by 81 publications

References 5 publications

High Serum Iron Is Associated with Increased Cancer Risk

High Serum Iron Is Associated with Increased Cancer Risk

HFEC282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease

Increased Prevalence of theHFE C282YHemochromatosis Allele in Women with Breast Cancer

Contact Info

Product

Resources

About